Advanced search×
×

Drug Discovery Today

Print ISSN
1359-6446
Electronic ISSN
1878-5832
Impact factor
6.422
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/13596446
Usage rank
363
Article count
2112
Free count
13
Free percentage
0.0061553
PDFs via platforms
CSA, Rcgp, Proquest, Sciencedirect from 1996, Gale, and Ingenta

  1. Novel therapeutic strategies for treatment of visceral leishmaniasis.

    Drug Discovery Today 18(23-24):1272 (2013) PMID 23973338

    Leishmaniasis reveals itself in two forms, cutaneous and visceral, but the later exerts serious complications and may lead to death, if untreated. The availability of limited number of antileishmanial chemotherapeutic agents, the high cost of treatment, growing incidences of resistance to first line...
  2. Non-peptidyl insulin mimetics as a potential antidiabetic agent.

    Drug Discovery Today 18(15-16):748 (2013) PMID 23603635

    Insulin has an important role in the maintenance of blood sugar. It is the only available therapeutic agent for the treatment of type 1 diabetes mellitus and there is a dire need for an oral substitute. Different categories of compounds including mono and di substituted benzoquinones, vanadium based...
  3. Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis.

    Drug Discovery Today 18(13-14):637 (2013) PMID 23579167

    In the 1990s there was a tremendous mood of optimism among pharmaceutical scientists that identification of disease-associated variations in the human genome would result in a surge of new drug targets (the 'gene-to-drug' mantra). To date the expected deluge of new drugs has not arrived. However, a...
  4. Quantitative characterization of non-contact microdispensing technologies for the sub-microliter range.

    Drug Discovery Today 18(9-10):435 (2013) PMID 23228651

    We characterize five established technologies and categorize them into valve-based and positive displacement-based technologies. Furthermore we introduce dispensing accuracy and precision in an 'intra-run', 'inter-run' and 'tip-to-tip' context as universally applicable performance parameters. A NIST...
  5. Translational research: the changing landscape of drug discovery.

    Drug Discovery Today 18(9-10):487 (2013) PMID 23247258

    Drug discovery represents the first step in the creation of new drugs, and takes place in academic institutions, biotech companies, and large pharmaceutical corporations. Until recently, these sectors have each operated independently with little collaboration between those at the forefront of discov...
  6. Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials.

    Drug Discovery Today 18(3-4):128 (2013) PMID 22903142 PMCID PMC3562372

    The in vivo zebrafish models have recently attracted great attention in molecular oncology to investigate multiple genetic alterations associated with the development of human cancers and validate novel anticancer drug targets. Particularly, the transparent zebrafish models can be used as a xenotran...
  7. Looking outward: content as a service starts to make sense.

    Drug Discovery Today 18(1-2):1 (2013) PMID 23041498

  8. Structural mass spectrometry in biologics discovery: advances and future trends.

    Drug Discovery Today 17(23-24):1323 (2012) PMID 22819924

    Mass spectrometry (MS) is one of the key techniques in protein characterization. In this article, the workflow for MS-based structural characterization of biologics in biopharmaceutical drug discovery is presented, including characterization of primary and higher order structures. Advances in MS tec...
  9. Applications of Connectivity Map in drug discovery and development.

    Drug Discovery Today 17(23-24):1289 (2012) PMID 22889966

    Genome-wide expression profiling of gene transcripts has been successfully applied in biomedical discovery for over a decade. Based on the premises of this technology, Connectivity Map provides a data-driven and systematic approach for discovering associations among genes, chemicals and biological c...
  10. Open PHACTS: semantic interoperability for drug discovery.

    Drug Discovery Today 17(21-22):1188 (2012) PMID 22683805

    Open PHACTS is a public-private partnership between academia, publishers, small and medium sized enterprises and pharmaceutical companies. The goal of the project is to deliver and sustain an 'open pharmacological space' using and enhancing state-of-the-art semantic web standards and technologies. I...